Recent Quotes (30 days)

You have no recent quotes
chg | %

Arch Biopartners Inc  

(Public, CNSX:ACH)   Watch this stock  
Find more results for ACH
Feb 20 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range     -
52 week 0.38 - 0.42
Open     -
Vol. 0.00
Mkt cap 21.41M
P/E     -
Div/yield     -
EPS -0.01
Shares 50.98M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -2229.01%
Operating margin - -2409.41%
EBITD margin - -2363.44%
Return on average assets -111.45% -159.01%
Return on average equity -860.84% -1243.98%
CDP Score - -


174 Spadina Ave Suite 502A
+1-647-4287031 (Phone)
+1-905-7704454 (Fax)

Website links


Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is engaged in developing new products and technology for sale to pharmaceutical and industrial companies. It has four technology platforms in its portfolio under development: MetaMx, synthetic molecules that target brain tumor initiating cells and invasive glioma cells; MetaBlok, a drug candidate for the potential treatment of sepsis and cancer metastasis; Borg, a peptide-solid surface interface for binding of peptides to solid surfaces to inhibit biofilm formation and reduce corrosion, and treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. The Company's wholly owned subsidiaries include Arch Biotech Inc., Arch Biophysics Inc. and Arch Cancer Therapeutics Inc.

Officers and directors

Richard Muruve President, Chief Executive Officer, Director
Daniel Muruve Chief Science Officer
Andrew Bishop Director
Richard Rossman M.D. Director
Claude Allary Independent Director
Conor M. Gunne Independent Director
Adrian J. Haigh Independent Director
Age: 56